| Literature DB >> 11486004 |
S Miyagawa1, H Murakami, Y Takahagi, R Nakai, M Yamada, A Murase, S Koyota, M Koma, K Matsunami, D Fukuta, T Fujimura, T Shigehisa, M Okabe, H Nagashima, R Shirakura, N Taniguchi.
Abstract
We have been successful in generating several lines of transgenic mice and pigs that contain the human beta-d-mannoside beta-1,4-N-acetylglucosaminyltransferase III (GnT-III) gene. The overexpression of the GnT-III gene in mice and pigs reduced their antigenicity to human natural antibodies, especially the Galalpha1-3Galbeta1-4GlcNAc-R, as evidenced by immunohistochemical analysis. Endothelial cell studies from the GnT-III transgenic pigs also revealed a significant down-regulation in antigenicity, including Hanganutziu-Deicher antigen, and dramatic reductions in both the complement- and natural killer cell-mediated pig cell lyses. Changes in the enzymatic activities of other glycosyltransferases, such as alpha1,3-galactosyltransferase, GnT-IV, and GnT-V, did not support cross-talk between GnT-III and these enzymes in the transgenic animals. In addition, we demonstrated the effect of GnT-III in down-regulating the xenoantigen of pig heart grafts, using a pig to cynomolgus monkey transplantation model, suggesting that this approach may be useful in clinical xenotransplantation in the future.Entities:
Mesh:
Substances:
Year: 2001 PMID: 11486004 DOI: 10.1074/jbc.M104359200
Source DB: PubMed Journal: J Biol Chem ISSN: 0021-9258 Impact factor: 5.157